{ "Phase 2A Trial of DT402 for Autism Spectrum Disorder", "This study is testing a drug called DT402 in adults with Autism Spectrum Disorder (ASD). DT402 is a psychoactive substance that affects brain chemicals like serotonin. The study aims to see how DT402 changes your symptoms related to socialization and communication. You might be able to join if you are an adult between 18 and 65 years old with an ASD diagnosis and significant challenges in social interaction and communication. The main way they will measure if the treatment is working is by looking at changes in your pain or symptom scores over time. The current status of this study is unclear, but it plans to enroll about 20 people.", "design": "This is an open-label study, meaning you and the researchers will know if you are receiving the study drug. It is a single-center study and plans to enroll about 20 adults.", "commitments": "You would receive a single dose of DT402. Your symptom scores will be measured at several points: before the dose, at 2, 4, 6, 8, and 24 hours after the dose, and again on day 15.", "compensation": "Not stated in the trial record.", "follow_up": "Your symptoms will be monitored up to 15 days after receiving the dose of DT402.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.